Anand Ashwin Patel

United States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Collaborators (6)

Girish Venkataraman

Asst Professor

University of Chicago Pritzker School of Medicine

UNITED STATES

Evan Chen

Dana-Farber Cancer Institute

UNITED STATES

Nicholas J. Short

UNITED STATES

Wendy Stock

University of Chicago

UNITED STATES

Musa Yilmaz

The University of Texas MD Anderson Cancer Center

UNITED STATES

Sunil Iyer

Columbia University

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anand Ashwin Patel

Research Interests

Explore related searches

Contact this professor

Articles (21)

Collaborators (6)

Girish Venkataraman

Evan Chen

Nicholas J. Short

Wendy Stock

Musa Yilmaz

Sunil Iyer

Make your next move.

Anand Ashwin Patel

Research Interests

Explore related searches

Contact this professor

Articles (21)

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.

SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms

Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.

Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.

Somatic co‐alteration signatures are prognostic in high‐grade TP53‐mutated myeloid neoplasms

Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.

Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.

Response and Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia

Durable responses in acute lymphoblastic leukaemia with the use of <scp>FLT3</scp> and <scp>IDH</scp> inhibitors

Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.

Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Targeted Therapy for MPNs: Going Beyond JAK Inhibitors.

Targeted Therapy for MPNs: Going Beyond JAK Inhibitors

Clinical and molecular response of acute myeloid leukemia harboring non-canonical &lt;i&gt;FLT3&lt;/i&gt; N676K driver mutations to contemporary FLT3 inhibitors

Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors

Collaborators (6)

Girish Venkataraman

Evan Chen

Nicholas J. Short

Wendy Stock

Musa Yilmaz

Sunil Iyer

Make your next move.

Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors